Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Division of Neurocritical Care, Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; Cerebrovascular Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio.
Department of Cardiothoracic Surgery, NYU Langone Health, New York, New York; Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
Ann Thorac Surg. 2019 Jul;108(1):52-58. doi: 10.1016/j.athoracsur.2019.01.016. Epub 2019 Feb 11.
Little data exist regarding reversal and resumption of antithrombotics after left ventricular assist device (LVAD)-associated intracranial hemorrhage.
Prospectively collected data of LVAD patients with intracranial hemorrhage were reviewed. Coagulopathy reversal agents, antithrombotic regimens, and thrombotic (venous thromboembolism, ischemic stroke, myocardial infarction) and hemorrhagic (recurrent intracranial hemorrhage, gastrointestinal bleed, anemia requiring transfusion) complications were recorded.
Of 405 patients, intracranial hemorrhage occurred in 39 (10%): 23 intracerebral hemorrhages, 10 subarachnoid hemorrhages, and 6 subdural hematomas. Of 27 patients who received antithrombotic reversal, 8 (30%) had inadequate coagulopathy reversal, and 3 of these patients had hemorrhage expansion or died before repeat imaging. One (4%) patient had a thrombotic complication (deep vein thrombosis). Antithrombotic therapy was resumed in 17 (100%) survivors in a median time 8 days for antiplatelet agents and 14 days for warfarin. Recurrent intracranial hemorrhage occurred within a median of 7 days of antithrombotic resumption, while ischemic stroke occurred in a median of 428 days. Patients who resumed antiplatelets alone (n = 4) had a trend toward more thrombotic events (1.37 versus 0.14 events/patient-year [EPPY]; p = 0.08), including more fatal thrombotic events (0.34 EPPY versus 0.08 EPPY; p = 0.89) compared with those resuming warfarin ± antiplatelet (n = 14). Nonfatal hemorrhage event rates were 0.34 EPPY in the warfarin ± antiplatelet versus 0 EPPY in the antiplatelet-alone group (p = 0.16). No fatal hemorrhagic events occurred.
Reversal of anticoagulation appears safe after LVAD-associated intracranial hemorrhage, though inadequate reversal was common. Resumption of warfarin ± antiplatelet was associated with fewer fatal and nonfatal thrombotic events compared with antiplatelets alone, though more nonfatal hemorrhage events occurred.
左心室辅助装置(LVAD)相关颅内出血后,逆转和恢复抗血栓治疗的相关数据很少。
回顾性分析颅内出血的 LVAD 患者的数据。记录凝血障碍逆转剂、抗血栓治疗方案以及血栓(静脉血栓栓塞、缺血性卒中和心肌梗死)和出血(颅内再出血、胃肠道出血、需要输血的贫血)并发症。
405 例患者中,39 例(10%)发生颅内出血:23 例脑出血,10 例蛛网膜下腔出血,6 例硬膜下血肿。在接受抗血栓治疗逆转的 27 例患者中,8 例(30%)存在凝血障碍逆转不足,其中 3 例在重复影像学检查前出现血肿扩大或死亡。1 例(4%)患者发生血栓并发症(深静脉血栓形成)。17 例幸存者(100%)在中位时间 8 天(抗血小板药物)和 14 天(华法林)后恢复抗血栓治疗。在抗血栓治疗恢复后中位 7 天内再次发生颅内出血,而缺血性卒中年中发生于中位 428 天。单独恢复抗血小板治疗的患者(n=4)有更多血栓事件的趋势(1.37 比 0.14 事件/患者年[EPPY];p=0.08),包括更多致命性血栓事件(0.34 EPPY 比 0.08 EPPY;p=0.89),与恢复华法林±抗血小板治疗的患者(n=14)相比。华法林±抗血小板治疗组的非致命性出血事件发生率为 0.34 EPPY,而单独抗血小板组为 0 EPPY(p=0.16)。没有致命性出血事件发生。
LVAD 相关颅内出血后,抗凝逆转似乎是安全的,尽管逆转不足很常见。与单独使用抗血小板药物相比,恢复华法林±抗血小板治疗与较少的致命性和非致命性血栓事件相关,尽管发生了更多的非致命性出血事件。